Rescuing the last-line polymyxins: achievements and challenges
Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …
Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
Agents of last resort: polymyxin resistance
The polymyxins, colistin (also known as polymyxin E) and polymyxin B, have a unique and
interesting history. Originally introduced in the 1950s for the treatment of infections due to …
interesting history. Originally introduced in the 1950s for the treatment of infections due to …
Synthetic macromolecules as therapeutics that overcome resistance in cancer and microbial infection
Synthetic macromolecular antimicrobials have shown efficacy in the treatment of multidrug
resistant (MDR) pathogens. These synthetic macromolecules, inspired by Nature's …
resistant (MDR) pathogens. These synthetic macromolecules, inspired by Nature's …
Clinical pharmacokinetics and pharmacodynamics of colistin
N Grégoire, V Aranzana-Climent, S Magréault… - Clinical …, 2017 - Springer
In this review, we provide an updated summary on colistin pharmacokinetics and
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …
pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment …
[HTML][HTML] Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy
Pseudomonas aeruginosa is characterized by a notable intrinsic resistance to antibiotics,
mainly mediated by the expression of inducible chromosomic β-lactamases and the …
mainly mediated by the expression of inducible chromosomic β-lactamases and the …
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to …
A Ardebili, A Izanloo, M Rastegar - Expert Review of Anti-infective …, 2023 - Taylor & Francis
Introduction The increasing prevalence of infections with multidrug-resistant (MDR),
extensively-drug resistant (XDR) or difficult-to-treat drug resistant (DTR) Gram-negative …
extensively-drug resistant (XDR) or difficult-to-treat drug resistant (DTR) Gram-negative …
Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections
N Palavutitotai, A Jitmuang, S Tongsai, P Kiratisin… - PloS one, 2018 - journals.plos.org
Background The incidence of nosocomial infections from extensively drug-resistant
Pseudomonas aeruginosa (XDR-PA) has been increasing worldwide. We investigated the …
Pseudomonas aeruginosa (XDR-PA) has been increasing worldwide. We investigated the …